causal

Risk-reduction drugs are a superior business model

Pharmaceutical companies and device makers earn far more by developing interventions that reduce risk, because—unlike antibiotics that cure and thereby consume their own demand—a risk-reduction drug can market to the entire population (anyone with even a small probability of a bad outcome) and have them take it for their entire life.

causalpending

Speaker

Guest

Evidence Quote

“If you have drugs with conventions that promise to treat risk, people are--possibly the whole population--could have even some small probability of a bad outcome. And be the market for a disease. And they might need to take this drug or intervention their entire life.”

Source

Robert Aronowitz on Risky Medicine— EconTalk
Created: 6/13/2026, 12:15:50 AM

Your notes

Loading notes...